Publicacions en què col·labora amb Maurizio Bendandi (35)

2021

  1. Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma

    Scientific Reports, Vol. 11, Núm. 1

2017

  1. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    Journal of Translational Medicine, Vol. 15, Núm. 1

  2. Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. MRP1-CD28 bi-specific oligonucleotide aptamers: Target costimulation to drug-resistant melanoma cancer stem cells

    Oncotarget, Vol. 7, Núm. 17, pp. 23182-23196

2015

  1. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia

    Biomaterials, Vol. 67, pp. 274-285

  2. Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma

    BioMed Research International, Vol. 2015

2014

  1. Idiotype vaccine production using hybridoma technology

    Methods in Molecular Biology, Vol. 1139, pp. 367-387

2013

  1. CD28 aptamers as powerful immune response modulators

    Molecular Therapy - Nucleic Acids, Vol. 2, pp. e98

  2. Successful idiotypic vaccination following stem cell allotransplant in lymphoma

    Leukemia and Lymphoma

2011

  1. BiovaxID®: A customized idiotype vaccine for the treatment of B-cell lymphoma

    Expert Review of Vaccines, Vol. 10, Núm. 12, pp. 1661-1669

  2. Idiotype vaccines for lymphoma therapy

    Expert Review of Vaccines, Vol. 10, Núm. 6, pp. 801-809

  3. Stem cell transplant and idiotypic vaccination for B-cell malignancies

    Current Topics in Medicinal Chemistry, Vol. 11, Núm. 13, pp. 1653-1660

2010

  1. Idiotype vaccines for human B-cell malignancies

    Current Pharmaceutical Design, Vol. 16, Núm. 3, pp. 300-307

  2. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma

    Annals of Oncology, Vol. 21, Núm. 12, pp. 2420-2427

2009

  1. Prolonged idiotypic vaccination against follicular lymphoma

    Leukemia and Lymphoma, Vol. 50, Núm. 1, pp. 47-53

  2. Vacuna idiotípica en el tratamiento del linfoma folicular: situación actual y perspectivas futuras

    Anales del sistema sanitario de Navarra, Vol. 32, Núm. 1, pp. 61-73

2007

  1. Anemia in chronic lymphatic leukemia: is erythropoietin the solution?

    Revista de medicina de la Universidad de Navarra, Vol. 51, Núm. 1, pp. 3-10

  2. Anti-idiotype antibodies in cancer treatment

    Oncogene, Vol. 26, Núm. 25, pp. 3594-3602

  3. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor

    Journal of Biological Chemistry, Vol. 282, Núm. 10, pp. 7405-7415

  4. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions

    Journal of Investigative Dermatology, Vol. 127, Núm. 7, pp. 1673-1680